chemotherapy versus abiraterone acetate in mhspca
Published 5 years ago • 739 plays • Length 4:25Download video MP4
Download video MP3
Similar videos
-
1:55
dr. sweeney on chemotherapy versus abiraterone for mcrpc
-
1:02
dr. oh on choosing ar-targeted therapy versus chemotherapy in mhspc
-
1:34
william oh, md: comparison of chemotherapy to a secondary hormone at the time of progression
-
2:20
mcrpc case impressions & adt abiraterone response
-
2:09
dr. charles ryan discusses abiraterone and enzalutamide for mcrpc
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
2:06
the role of abiraterone in prostate cancer
-
7:58
abiraterone and chemotherapy in crpc
-
1:13
abiraterone with low-dose prednisone in prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
2:07
what is the difference between classical chemotherapy and novel targeted therapy?
-
3:08
targeted prostate cancer therapies vs. chemotherapy: what’s the difference?
-
4:59
case of mhspca progressing to mcrpc
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
1:18
results of the latitude trial in high-risk metastatic hormone-naive prostate cancer
-
1:10
abiraterone: a new therapy for metastatic prostate cancer | memorial sloan kettering
-
1:26
dr. oh discusses choosing abiraterone in prostate cancer
-
10:00
results from acis trial of apalutamide abiraterone/prednisone in patients with chemo-naive mcrpc